In January 2017, independent news organisation ProPublica revealed that Tom Price, a Republican congressman nominated by Donald Trump to become head of the Department of Health and Human Services, had persistently lobbied on behalf of Arbor Pharmaceuticals, which owns the marketing rights to BiDil, to remove a certain study from a government website.
